NASDAQ:APTO Aptose Biosciences (APTO) Stock Price, News & Analysis $0.57 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.55▼$0.6050-Day Range$0.57▼$1.1652-Week Range$0.55▼$5.10Volume95,181 shsAverage Volume69,432 shsMarket Capitalization$10.29 millionP/E RatioN/ADividend YieldN/APrice Target$14.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Aptose Biosciences alerts: Email Address Aptose Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,511.5% Upside$14.83 Price TargetShort InterestHealthy0.54% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.16 out of 5 starsMedical Sector555th out of 936 stocksBiological Products, Except Diagnostic Industry85th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingAptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAptose Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Aptose Biosciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.54% of the float of Aptose Biosciences has been sold short.Short Interest Ratio / Days to CoverAptose Biosciences has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptose Biosciences has recently decreased by 13.12%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAptose Biosciences does not currently pay a dividend.Dividend GrowthAptose Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APTO. Previous Next 2.5 News and Social Media Coverage News SentimentAptose Biosciences has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aptose Biosciences this week, compared to 0 articles on an average week.Search InterestOnly 4 people have searched for APTO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows11 people have added Aptose Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptose Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Aptose Biosciences is held by insiders.Percentage Held by InstitutionsOnly 26.62% of the stock of Aptose Biosciences is held by institutions.Read more about Aptose Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptose Biosciences is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptose Biosciences is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Aptose Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. About Aptose Biosciences Stock (NASDAQ:APTO)Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Read More APTO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APTO Stock News HeadlinesJuly 26 at 3:12 AM | americanbankingnews.comAptose Biosciences Inc. (NASDAQ:APTO) Receives Average Recommendation of "Buy" from BrokeragesJuly 24 at 4:34 AM | americanbankingnews.comStockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO)July 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."July 19, 2024 | globenewswire.comAptose Announces Receipt of Deficiency Notice from NasdaqJuly 17, 2024 | americanbankingnews.comAptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.comJune 18, 2024 | globenewswire.comAptose Announces Results from Annual and Special Meeting of ShareholdersJune 14, 2024 | globenewswire.comAptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid CongressJune 3, 2024 | globenewswire.comAptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 27, 2024 | Weiss Ratings (Ad)The next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.May 31, 2024 | globenewswire.comAptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 14, 2024 | globenewswire.comAptose Reports Results for the First Quarter 2024May 6, 2024 | globenewswire.comAptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024March 29, 2024 | investing.comAptose Biosciences target cut, maintains buy rating on new drug developmentMarch 28, 2024 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Reports Results for the Fourth Quarter and Full Year 2023March 27, 2024 | finance.yahoo.comAptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | msn.comEdgewood secures $20m in Series A for clinical development of cancer therapyMarch 27, 2024 | benzinga.comRecap: Aptose Biosciences Q4 EarningsMarch 26, 2024 | globenewswire.comAptose Reports Results for the Fourth Quarter and Full Year 2023See More Headlines Receive APTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:APTO CUSIPN/A CIK882361 Webwww.aptose.com Phone858-926-2730Fax905-234-2120Employees31Year FoundedN/APrice Target and Rating Average Stock Price Target$14.83 High Stock Price Target$38.00 Low Stock Price Target$5.00 Potential Upside/Downside+2,511.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($6.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,003.74% Return on Assets-257.64% Debt Debt-to-Equity RatioN/A Current Ratio0.97 Quick Ratio0.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.19) per share Price / Book-2.99Miscellaneous Outstanding Shares18,110,000Free Float17,276,000Market Cap$10.29 million OptionableNo Data Beta1.26 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. William G. Rice Ph.D. (Age 59)Chairman, Pres & CEO Mr. Gregory K. Chow CPA (Age 45)MBA, BA, Sr. VP, CFO & Principal Accounting Officer Mr. Ernest Kitt B.S.M.S, VP of Devel. & Technical OperationsDr. Stephen B. Howell (Age 73)Chief Medical Officer Mr. Peter MurrayDirector of Clinical Devel.Key CompetitorsOKYO PharmaNASDAQ:OKYOCurisNASDAQ:CRISIN8bioNASDAQ:INABAchilles TherapeuticsNASDAQ:ACHLQuince TherapeuticsNASDAQ:QNCXView All CompetitorsInsidersBernd R SeizingerBought 17,000 shares on 9/22/2023Total: $53,380.00 ($3.14/share)View All Insider Transactions APTO Stock Analysis - Frequently Asked Questions How have APTO shares performed this year? Aptose Biosciences' stock was trading at $2.54 at the beginning of the year. Since then, APTO shares have decreased by 77.6% and is now trading at $0.5680. View the best growth stocks for 2024 here. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (NASDAQ:APTO) announced its quarterly earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.09. When did Aptose Biosciences' stock split? Aptose Biosciences's stock reverse split before market open on Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO? 8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend. Who are Aptose Biosciences' major shareholders? Aptose Biosciences' top institutional shareholders include Concourse Financial Group Securities Inc.. Insiders that own company stock include William G Rice, Bernd R Seizinger, Denis R Burger, Erich Platzer, Rafael Bejar and Donald R Jr Wilson. View institutional ownership trends. How do I buy shares of Aptose Biosciences? Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL) and CymaBay Therapeutics (CBAY). This page (NASDAQ:APTO) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APTO Stock Alerts